cardiovascular
diseas
consid
major
caus
morbid
mortal
throughout
world
past
sever
year
great
achiev
made
treatmentmanag
cardiovascular
diseas
depend
use
experiment
anim
model
use
diseas
model
preclin
research
larg
amount
inform
gener
outlin
pathogenesi
progress
mechan
underli
cardiovascular
diseas
cellular
molecular
level
allow
develop
mani
effect
treatment
strategi
cardiovascular
diseas
model
develop
mani
speci
includ
larg
anim
swine
dog
well
small
anim
rat
mice
small
anim
model
applic
research
work
compar
larg
anim
model
due
inexpens
conveni
handl
vast
amount
scientif
literatur
avail
review
mainli
focu
variou
method
use
investig
creat
small
anim
model
cardiac
diseas
myocardi
infarct
mi
dilat
cardiomyopathi
dcm
heart
failur
hf
myocard
cardiac
hypertrophi
ch
relat
stem
cell
treatment
diseas
mi
one
lead
caus
death
world
induc
blockag
coronari
arteri
result
atherosclerosi
thrombosi
character
necrosi
myocardiocyt
due
reduct
blood
suppli
convent
clinic
treatment
percutan
coronari
intervent
coronaryarteri
bypass
graft
surgeri
anti
dissolut
thrombot
therapi
reduc
death
rate
certain
extent
heart
transplant
greatli
restrict
due
limit
sourc
donor
heart
therefor
effect
approach
urgent
need
treat
diseas
basi
anim
model
establish
experiment
research
mechan
underli
develop
cardiovascular
diseas
cellular
molecular
level
clarifi
potenti
treatment
option
use
protein
gene
stem
cell
therapi
propos
achiev
satisfactori
result
occlud
differ
region
coronari
arteri
via
thoracotomi
induc
mi
use
decad
ligat
left
anterior
descend
coronari
arteri
lad
creat
anterior
wall
infarct
left
ventricl
lv
describ
mani
worker
surgic
procedur
divid
three
step
brief
heart
anim
anaesthesia
expos
follow
left
thoracotomi
fourth
intercost
space
pericardium
care
broken
lad
ligat
sutur
place
distal
tip
left
auricl
procedur
consid
success
electrocardiogram
ecg
show
stsegment
elev
anterior
wall
left
ventricl
becom
whitish
final
lung
inflat
chest
close
perman
ligat
lad
caus
irrevers
damag
myocardium
stabl
easili
reproduc
extens
employ
studi
mi
therapi
use
techniqu
cell
implant
genet
modif
administr
cytokin
ligat
lad
also
produc
hf
model
model
subsequ
remov
occlus
howev
difficulti
oper
small
rodent
particularli
mice
rel
high
surgic
mortal
due
size
wound
creat
address
addit
coronari
ligat
procedur
often
give
rise
apic
aneurysmat
infarct
variabl
size
surgic
procedur
cauter
cryoinjuryinduc
mi
previous
studi
use
variou
anim
model
brief
heart
expos
follow
intercost
thoracotomi
cauter
cryoinjuri
induc
electrocoagul
knife
second
cryoprob
respect
anterior
lv
free
wall
posit
probe
set
accur
use
pulmonari
arteri
anatom
landmark
mi
caus
cauter
cryoinjuri
stabl
easili
produc
short
period
time
without
interfer
coronari
arteri
collater
circul
particularli
suitabl
use
small
anim
mous
necrosi
myocardiocyt
ascrib
tissu
damag
caus
burn
ultralow
temperatur
unfortun
cauter
cryoinjuri
guarante
induc
myocardium
ischemia
tissu
damag
close
mimic
natur
ischemiainiti
infarct
fact
myocardi
injuri
cauter
cryoinjuri
show
pathophysiolog
chang
associ
myocardi
infarct
balloon
occlus
model
develop
percutan
translamin
coronari
angioplasti
appli
larg
anim
model
cohen
et
al
develop
occlus
model
small
anim
encircl
superfici
branch
rabbit
left
coronari
arteri
balloon
occlud
briefli
left
thoracotomi
open
end
balloon
occlud
place
around
branch
expos
left
coronari
arteri
lca
occlud
connect
vacuum
pump
compress
air
control
balloon
inflat
coronari
occlus
use
model
reduc
mortal
size
surgic
wound
compar
lad
ligationinduc
mi
procedur
reliabl
reproduc
allow
accur
posit
balloon
make
first
choic
model
induc
postinfarct
reperfus
howev
balloon
angioplasti
requir
high
level
surgic
expertis
easili
applic
small
anim
without
extens
train
druginduc
myocardi
ischemia
conveni
procedur
sinc
requir
complic
surgeri
isoproterenol
adriamycin
ergonovin
often
use
induc
mi
signal
et
al
induc
myocardi
ischemia
rat
isoproterenol
synthet
agonist
similarli
chagoya
et
al
develop
rat
mi
model
utilis
isoproterenol
arteaga
de
murphi
group
success
duplic
mi
model
rat
subcutan
inject
isoproterenol
arnold
et
al
creat
ischemia
model
rabbit
intraperiton
inject
adriamycin
druginduc
ischemia
easili
achiev
sinc
increas
myocardi
oxygen
consumpt
induc
coronari
arteri
spasm
reduc
blood
flow
howev
drug
safeti
difficulti
accur
posit
infarct
region
make
model
rare
use
clinic
research
studi
use
myocardi
infarct
anim
model
indic
transplant
mesenchym
stem
cell
msc
umbil
cord
blood
cell
bonemarrowderiv
haematopoiet
stem
cell
skelet
myoblast
endotheli
progenitor
cell
epc
cardiac
stem
cell
embryon
stem
cell
esc
inducedpluripot
stem
cell
potenti
improv
function
ventricular
muscl
mi
clinic
trial
also
produc
encourag
result
howev
current
experiment
evid
suggest
benefit
cell
therapi
modest
sever
recent
review
summar
systemat
applic
stem
cell
follow
mi
past
decad
shown
translat
potenti
benefit
stem
cell
therapi
actual
clinic
practic
still
need
lot
work
mani
barrier
would
need
overcom
therapi
attain
full
potenti
dcm
primari
myocardi
diseas
character
chamber
dilat
associ
impair
systol
diastol
function
start
asymptomat
lv
dilat
impair
systol
function
exerciseinduc
symptom
final
overt
congest
heart
failur
chf
onset
dcm
link
viral
infect
genet
abnorm
autoimmun
mechan
number
anim
model
dcm
develop
elucid
mechan
respons
pathophysiolog
featur
dcm
establish
potenti
treatment
strategi
section
review
focus
viral
infect
genet
abnorm
autoimmun
anim
model
applic
stem
cell
treat
dcm
increas
evid
show
larg
proport
dcm
case
mediat
autoimmun
process
variou
antimyocardi
antibodi
circul
serum
associ
myocyt
injuri
detect
dcm
patient
furthermor
famili
occurr
dcm
presenc
autoantibodi
abnorm
cytokin
profil
rel
asymptomat
lv
enlarg
account
case
suggest
involv
abnorm
humor
cellular
immun
earli
develop
diseas
receptor
antibodi
second
extracellular
receptor
loop
repres
potent
selfantigen
induc
dcm
matsui
et
al
use
rabbit
model
first
present
data
develop
biventricular
dilat
found
upregul
total
cardiac
receptor
follow
immun
peptid
intraperiton
inject
blood
lymphocyt
either
immun
anti
rabbit
dcm
patient
immunodefici
mice
avoid
expect
immun
reaction
rabbit
human
nonself
protein
lead
earli
stage
cardiac
dilat
treatment
mice
certain
human
leukocyt
antigen
allel
also
induc
autoimmun
myocard
follow
subsequ
develop
dcm
daniel
et
al
induc
dcm
mous
model
applic
kxxsmotif
autoimmun
dcm
model
also
creat
viral
infect
immun
heartspecif
autoantigen
genet
predispos
strain
viral
myocard
common
caus
acquir
dcm
human
pathogenesi
viral
myocard
pathophysiolog
featur
dcm
depend
viral
strain
genet
background
transduct
coxsacki
viru
genom
construct
cardiacspecif
promot
transgen
mice
induc
dcm
featur
consist
human
cardiomyopathi
recent
evid
show
coxsacki
viru
myocard
lead
dcm
acut
coronaviru
infect
also
result
virusinduc
myocard
chf
infect
nearli
half
rabbit
show
increas
heart
weight
heart
weighttobodi
weight
ratio
biventricular
dilat
myocyt
hypertrophi
myocardi
fibrosi
myocard
similar
develop
dcm
murin
aid
maid
retroviru
induc
dcm
absenc
chronic
cardiac
inflamm
suggest
maid
retrovir
infect
lead
dcm
without
myocard
approxim
dcm
patient
gene
mutat
affect
myosin
heavi
chain
cardiac
actin
tropomyosin
troponin
induc
function
impair
refer
protein
recent
investig
focus
genet
mechan
stress
pathway
cytoskelet
abnorm
signal
pathway
ch
hf
dcm
yasuhiro
et
al
focus
mous
model
dcm
togeth
commentari
natur
occur
dcm
hamster
base
subcellular
local
potenti
function
import
gene
product
involv
number
experiment
studi
clinic
trial
support
cellular
cardiomyoplasti
promis
therapeut
strategi
improv
cardiac
function
acut
mi
howev
much
less
inform
avail
therapeut
potenti
msc
dcm
noritoshi
et
al
investig
effect
msc
dcm
anim
follow
immun
result
show
msc
transplant
increas
capillari
densiti
decreas
collagen
volum
fraction
myocardium
result
decreas
lv
enddiastol
pressur
bone
marrowderiv
mononuclear
cell
therapi
dcm
limit
cellular
apoptosi
inflammatori
oxid
respons
upregul
express
pkc
energi
transcript
factor
improv
lv
function
addit
intracoronari
administr
bone
marrowderiv
progenitor
cell
improv
coronari
microvascular
function
dcm
henc
stem
cell
transplant
great
potenti
new
therapeut
strategi
treatment
dcm
hf
associ
surviv
year
use
anim
model
indispens
understand
pathophysiolog
hf
evalu
efficaci
effici
novel
therapeut
approach
gene
therapi
use
mechan
devic
new
surgic
procedur
section
present
common
vivo
model
use
studi
hf
method
allow
complet
partial
occlus
coronari
arteri
branch
anim
model
henc
applic
induc
hf
coronari
stenosi
investig
hibern
myocardium
briefli
left
anterolater
thoracotomi
perform
follow
incis
pericardium
branch
lca
expos
hydraul
occlud
place
around
vessel
occlud
inflat
induc
partial
stenosi
complet
occlus
ultrason
flow
probe
place
distal
occlud
control
degre
occlus
record
downstream
flow
lca
ameroid
constrictor
also
implant
similar
way
bodi
temperatur
casein
plastic
ring
around
vessel
gradual
narrow
due
hygroscop
properti
materi
complex
place
hydraul
occlud
ameroid
constrictor
mean
procedur
appropri
use
small
anim
model
investig
miinduc
hf
pfeffer
et
al
creat
hf
rat
coronari
arteri
ligat
rat
infarct
size
greater
develop
chf
day
symptom
elev
fill
pressur
reduc
cardiac
output
minim
capac
respond
pre
afterload
stress
impair
lv
function
close
associ
extent
myocardi
loss
anim
mortal
hf
seem
straindepend
sinc
spraguedawley
lewi
rat
mortal
rate
respect
coronari
arteri
embolisationinduc
hf
base
intracoronari
embolis
microspher
agaros
polystyren
bead
intracoronari
inject
thrombin
autogen
blood
fibrinogen
sabbah
et
al
use
dog
underw
cathetermedi
intracoronari
embolis
week
apart
embolis
discontinu
eject
fraction
lv
less
model
coronari
arteri
embolis
increas
lv
enddiastol
pressur
accompani
signific
rise
pulmonari
arteri
wedg
pressur
system
vascular
resist
three
month
embolis
patchi
myocardi
fibrosi
lv
hypertrophi
observ
heart
also
increas
plasma
level
atrial
natriuret
peptid
norepinephrin
well
reduct
number
ltype
calcium
channel
activ
protein
level
sr
model
mimic
clinic
situat
patient
hf
acut
coronari
syndrom
sinc
embolisationinduc
atherosclerot
thrombot
debri
deposit
coronari
microcircul
howev
one
disadvantag
model
difficulti
accur
control
locat
length
coronari
arteri
occlus
incomplet
narrow
coronari
arteri
similar
observ
coronari
arteri
occlus
anim
model
establish
mimic
chronic
hf
brief
thoracotomi
perform
chosen
anim
model
probe
copper
wire
insert
epicardium
along
lca
lca
ligat
probe
insid
mm
origin
probe
remov
result
averag
reduct
lumin
diamet
st
segment
ecg
transient
elev
coronari
occlus
oper
success
excess
coronari
arteri
occlus
may
induc
persist
st
segment
elev
even
remov
probe
hf
may
occur
result
chronic
cardiac
ischemia
coronari
ligat
procedur
may
inevit
includ
ligatur
muscl
mass
could
induc
vessel
stenosi
maxim
rest
coronari
blood
flow
decreas
day
follow
oper
repar
fibrosi
myocytolyt
necrosi
well
myocyt
hypertrophi
also
occur
model
lack
predict
reliabl
degre
progress
stenosi
adjust
sever
week
complet
occlus
coronari
arteri
develop
interestingli
gradual
increas
stenosi
may
prompt
format
collater
vessel
similar
situat
observ
patient
current
therapi
aim
larg
attenu
patholog
remodel
occur
injuri
reduc
risk
factor
hf
studi
anim
model
indic
transplant
bonemarrow
deriv
stem
cell
msc
epc
autolog
umbil
cord
blood
mononuclear
cell
potenti
improv
function
ventricular
muscl
hf
number
studi
show
improv
cardiac
function
bone
marrowderiv
stem
cell
directli
implant
howev
limit
differenti
bone
marrow
cell
cardiovascular
cell
type
suggest
benefici
effect
independ
tissu
regener
group
shown
epc
great
promis
potenti
therapeut
agent
howev
research
requir
enhanc
therapeut
effici
epc
hf
myocard
defin
inflamm
heart
muscl
resembl
heart
attack
without
blockag
coronari
arteri
myocard
often
induc
viral
infect
parvoviru
less
commonli
nonvir
pathogen
borrelia
burgdorferi
lyme
diseas
trypanosoma
cruzi
hypersensit
respons
drug
myocard
therefor
infect
heart
inflammatori
infiltr
caus
damag
heart
muscl
may
may
result
death
heart
tissu
procedur
produc
anim
model
eam
activ
immun
cardiac
myocin
previous
describ
immunogen
inject
subcutan
mous
day
later
second
dose
immunogen
emulsifi
complet
freund
adjuv
cfa
administ
day
first
immun
mous
euthan
heart
immedi
remov
fix
formalin
hour
stain
histopatholog
assess
perform
ascertain
whether
eam
establish
rapid
determin
induct
eam
also
made
analyz
specif
serum
marker
cardiac
injuri
cardiac
troponin
ctni
cardiac
troponin
ctnt
two
protein
associ
myocyt
contractil
apparatu
releas
serum
myocyt
injur
serv
marker
myocyt
injuri
ctni
highli
sensit
specif
myocard
mice
day
immun
sensit
ctnt
measur
maxim
day
ctni
ctnt
measur
superior
measur
ckmb
detect
murin
eam
protocol
eam
induct
adopt
transfer
cardiac
myosinstimul
cell
report
breif
donor
mice
week
old
immun
cardiac
myosin
emulsifi
cfa
spleen
harvest
mice
day
first
immun
spleen
incub
steril
tissu
cultur
flask
hour
lymphocyt
separ
red
blood
cell
dead
cell
ficollhypaqu
gradient
centrifug
cell
enrich
b
cell
remov
cytotox
elimin
use
class
ii
antibodi
complement
cell
inject
intraven
tail
vein
recipi
scid
mice
day
first
immun
mous
euthan
heart
immedi
remov
fix
formalin
hour
stain
histopatholog
assess
perform
ascertain
whether
eam
establish
model
ideal
studi
role
specif
cellular
effector
induct
pathogenesi
eam
applic
scid
mice
function
b
cell
protocol
induc
eam
activ
immun
bordetella
known
brief
emuls
select
immunogen
cardiac
myosin
cardiac
myosin
peptid
prepar
day
appropri
volum
immunogen
subcutan
inject
femal
lewi
rat
solut
b
pertussi
prepar
pb
inject
rat
intraven
day
day
first
immun
rat
euthan
heart
immedi
remov
fix
formalin
hour
stain
histopatholog
assess
perform
ascertain
whether
eam
establish
inject
cardiac
myosin
b
pertussi
way
induc
eam
rat
allow
compar
studi
mechan
underli
diseas
develop
human
infect
common
virus
adenoviru
enteroviru
epsteinbarr
viru
human
herp
viru
parvoviru
cytomegaloviru
may
activ
tcell
associ
cytokin
mechan
result
autoimmun
myocard
virus
induc
initi
myocardi
injuri
caus
continu
low
grade
inflamm
endur
myocardi
damag
repar
fibrosi
inflammatori
cell
also
produc
matrixdegrad
proteas
lead
lv
dilat
cardiac
dysfunct
similar
autoimmun
myocard
direct
viru
inject
caus
myocard
three
phase
initi
phase
frequent
pass
without
symptom
sinc
initi
damag
often
prevent
innat
immun
respons
second
phase
result
immun
dysregul
trigger
initi
cardiomyocyt
injuri
initi
cellular
humor
immun
respons
may
improv
outcom
phase
convers
respons
harm
effect
phase
part
due
molecular
mimicri
caus
mimick
epitop
share
viral
cardiac
antigen
final
third
phase
typic
dcm
develop
result
extens
myocardi
injuri
howev
difficult
determin
viru
doseconcentr
requir
induc
myocard
detect
inflamm
myocardium
first
phase
limit
applic
preclin
research
stem
cell
play
critic
role
pathogenesi
outcom
myocard
recent
studi
describ
role
differ
stem
cell
type
subtyp
product
mediat
cardiac
dysfunct
myocard
kania
g
et
al
vitro
cultureexpand
specif
popul
bone
marrowderiv
progenitor
cell
healthi
heart
tissu
inject
cell
intraven
autoimmunemyocard
anim
model
msc
also
angiogen
myogen
paracrin
action
treatment
eam
okada
h
et
al
determin
whether
msc
transplant
attenu
eam
result
show
msc
transplant
reduc
sever
eam
induc
neovascular
inhibit
inflammatori
cytokin
product
weener
et
al
investig
effect
deliv
spleenderiv
epc
rat
model
inflammatorymedi
myocardi
damag
found
epc
caus
function
improv
cardiac
perform
evid
higher
fraction
shorten
reduc
scar
tissu
thicken
ventricular
wall
wang
et
al
use
esc
attenu
viral
myocard
found
tail
vein
inject
esc
significantli
increas
surviv
viral
myocard
mice
decreas
necrosi
infiltr
inflammatori
cell
studi
taken
togeth
demonstr
potenti
stem
cell
therapi
treat
myocard
ch
adapt
respons
heart
pressur
overload
howev
long
term
hypertrophi
cardiomyocyt
maintain
normal
function
eventu
hf
develop
ch
common
featur
fail
myocardium
progress
cardiovascular
diseas
eg
hypertens
mi
hf
close
relat
patholog
chang
mani
investig
studi
mechan
underli
ch
recent
research
show
ch
complic
dynam
process
associ
mani
genet
molecular
chang
relat
regul
seri
signal
pathway
express
cardiac
fetal
gene
enhanc
protein
synthesi
interestingli
increas
cardiac
protein
synthesi
directli
caus
enlarg
cardiomyocyt
variou
chemic
factor
well
mechan
stimul
contribut
develop
hypertroph
respons
also
basi
establish
cell
anim
model
mani
laboratori
induc
hypertroph
phenotyp
neonat
adult
cardiomyocyt
use
mediat
angiotensin
ii
leptin
akimasa
koga
group
construct
adenoviru
vector
carri
human
wildtyp
gene
abl
prevent
phenylephrin
hypertroph
respons
galindo
colleagu
compar
transcript
differ
isoproterenolinduc
exerciseinduc
ch
mice
report
stem
cell
therapi
follow
ch
gener
ch
suppress
accompani
symptom
follow
ischem
injuri
hf
treatment
team
found
postinfarct
hypertroph
phenotyp
inhibit
erythropoietin
treatment
activ
stem
cell
mobil
migrat
infarct
heart
use
small
anim
diseas
model
preclin
research
worker
aquir
larg
amount
inform
pathogenesisprogress
cardiovascular
diseas
aid
develop
effect
treatment
option
anim
model
effect
scientif
tool
studi
molecular
mechan
stem
cell
base
therapi
cardiovascular
diseas
potenti
provid
power
approach
discov
new
drug
